RVMD Stock Recent News

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Ryan Asay - Senior Vice President-Corporate Affairs Mark Goldsmith - Chairman and Chief Executive Officer Steve Kelsey - President-Research and Development Wei Lin - Chief Medical Officer Jack Anders - Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Marc Frahm - TD Cowen Eric Joseph - J.P. Morgan Jonathan Chang - Leerink Partners Kelly Shi - Jefferies Ellie Merle - UBS Operator Good day, and thank you for standing by.

REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2025, and provided an update on corporate progress.

REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer

REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 – 30, 2025.

REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in in two upcoming investor conferences.

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Ryan Asay - Senior Vice President-Corporate Affairs Mark Goldsmith - Chairman and Chief Executive Officer Jack Anders - Chief Financial Officer Steve Kelsey - President-Research and Development Wei Lin - Chief Medical Officer Conference Call Participants Eric Joseph - J.P. Morgan Marc Frahm - TD Cowen Michael Schmidt - Guggenheim Ben Burnett - Stifel Laura Prendergast - Raymond James Jay Olson - Oppenheimer Joe Catanzaro - Piper Sandler Poorna Kannan - Needham & Company Alex Bouilloux - Barclays Bank Operator Good day, and thank you for standing by.

Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026 Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancer Company anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of treatment for pancreatic cancer in the second half of 2025 Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif.

REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A.

REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2024 on Wednesday, February 26, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year and provide an update on corporate progress.